Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up
- PMID: 40576906
- PMCID: PMC12204890
- DOI: 10.1007/s12022-025-09866-z
Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up
Abstract
The clinical behavior of well-differentiated pancreatic neuroendocrine tumors (PanNETs) is difficult to predict. In order to define, more accurately, prognosticators for patients with a surgically resected PanNET, the pathologic features and Ki-67 immunolabeling indexes of PanNETs resected from 904 consecutive patients at an academic tertiary care hospital were correlated with patient outcome. The mean patient age at surgery was 56.6 years (SD 14.0), 477 were male (52.8%), and 7882 person-years of follow-up were obtained (mean 8.8 years, SD 6.5). The 10-year survival was 81% (95% CI: 77,86%) for patients with G1 PanNETs (Ki-67 <3%), 68% (95% CI: 61,76%) for patients with G2a PanNETs (Ki-67 3 - <10%), 44% (95% CI: 29,66%) for patients with G2b PanNETs (Ki-67 of 10%- ≤20%), and 23% (95% CI: 8,61%) for patients with G3 PanNETs. Vascular invasion (HR 3.0, p <0.0001), tumor size ≥ 2 cm (HR 2.88, p <0.0001), perineural invasion (HR 2.42, p<0.0001), and positive margins (HR 2.18, p <0.0001) were associated with worse overall survival. Insulinoma (HR 0.34, p=3e-04), sclerosing variant (HR 0.47, p=0.05), and cystic variant (HR 0.61, p=0.05) were associated with improved overall survival. T, N and M stages were all statistically significant classifiers of overall survival. Similar associations were found with respect to disease relapse. There was a significant (P<0.001) increase in the proportion of patients diagnosed with stage I vs stage IV disease over time. This study supports the classification of PanNETs into four grades (G1, G2a, G2b, and G3) based on Ki-67 labeling, which allows a more accurate prognostic assessments of patients.
Keywords: Grade; Ki-67; PanNET; Prognosis; Stage; Vascular invasion; Well-differentiated pancreatic neuroendocrine tumor.
© 2025. The Author(s).
Conflict of interest statement
Declarations. The authors declare that they do not have any financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Competing interests: The authors declare no competing interests.
Figures

Update of
-
Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: An Analysis of 904 Patients with 7882 Person-Years of Follow-Up.medRxiv [Preprint]. 2025 Apr 3:2025.04.01.25325055. doi: 10.1101/2025.04.01.25325055. medRxiv. 2025. Update in: Endocr Pathol. 2025 Jun 27;36(1):24. doi: 10.1007/s12022-025-09866-z. PMID: 40236435 Free PMC article. Updated. Preprint.
Similar articles
-
Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: An Analysis of 904 Patients with 7882 Person-Years of Follow-Up.medRxiv [Preprint]. 2025 Apr 3:2025.04.01.25325055. doi: 10.1101/2025.04.01.25325055. medRxiv. 2025. Update in: Endocr Pathol. 2025 Jun 27;36(1):24. doi: 10.1007/s12022-025-09866-z. PMID: 40236435 Free PMC article. Updated. Preprint.
-
Clinical and biological heterogeneity of Grade 2 digestive neuroendocrine neoplasms: prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies. A longitudinal study.J Endocrinol Invest. 2025 Jun;48(6):1483-1493. doi: 10.1007/s40618-025-02552-1. Epub 2025 Feb 19. J Endocrinol Invest. 2025. PMID: 39969798
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Prognostic Factors and Management Approaches for Small Nonfunctional Pancreatic Neuroendocrine Tumors: Insights from SEER Data.J Invest Surg. 2025 Jul 7;38(1):2528340. doi: 10.1080/08941939.2025.2528340. Epub 2025 Jul 15. J Invest Surg. 2025. PMID: 40661037
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
References
-
- Pathak, S., Starr, J. S., Halfdanarson, T. & Sonbol, M. B. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab 18, 377-385 (2023). 10.1080/17446651.2023.2237593 - PubMed
-
- Thiis-Evensen, E. & Boyar Cetinkaya, R. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021. J Neuroendocrinol 35, e13264 (2023). 10.1111/jne.13264 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical